Medications for Alcohol Use Disorder Market

The medications for alcohol use disorder market is experiencing robust expansion as evolving care models prioritize access, adherence, and integrated approaches. Increasing recognition of alcohol use disorder’s complexity, alongside broader healthcare transformation, positions pharmacotherapy as a vital pillar for long-term recovery strategies.

Market Snapshot: Medications for Alcohol Use Disorder Market

The Medications for Alcohol Use Disorder Market grew from USD 1.10 billion in 2025 to USD 1.20 billion in 2026. It is expected to continue growing at a CAGR of 10.11%, reaching USD 2.17 billion by 2032. This sustained momentum reflects heightened clinical adoption and expanded payer focus on outcome-driven, integrated solutions in alcohol use disorder (AUD) care.

Scope & Segmentation

Drug Classes: Includes medications for relapse prevention, craving reduction, and aversive mechanisms, each tailored to the patient’s clinical profile and treatment goals.
Routes of Administration: Oral regimens, long-acting injectables, and emerging delivery systems impact patient initiation and adherence by aligning with varying real-world treatment settings.
Care Settings: Primary care, specialty addiction centers, emergency departments, outpatient behavioral health clinics, and digital health programs represent the core touchpoints for pharmacotherapy initiation and management.
Distribution Channels: Hospital, retail, and specialty pharmacies, along with digital and telehealth-enabled platforms, shape prescription fulfillment, benefits navigation, and ongoing support.
End-User Segments: Providers, payers, government programs, and non-traditional care coordinators all influence uptake, with emphasis on coordinated workflows and patient access.
Geographies Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific, each exhibiting distinct trends based on policy, infrastructure, and cultural context.

Key Takeaways for Strategic Decision-Makers

Integrated care adoption: Programs are aligning pharmacotherapy with measurement-based care, ongoing monitoring, and diversified treatment outcomes that extend beyond abstinence.
Expanded prescriber base: Primary care and behavioral health networks are increasingly central, reinforcing the need for prescriber education and practical, streamlined workflows.
Comorbidity complexity: Coexisting conditions complicate medication selection, driving demand for solutions that prioritize tolerability, safety, and compatibility with behavioral therapies.
Channel optimization: Predictable access, rapid fulfillment, and coordinated pharmacy services significantly enhance adherence and reduce treatment abandonment risk.
Regional diversity: Uptake varies with reimbursement structures and cultural attitudes toward addiction, requiring localized approaches and culturally competent engagement.
Implementation-first focus: Competitive advantage now relies on field support, provider enablement, and real-world adherence solutions, not just clinical trial profiles.

Tariff Impact on Supply Chain & Market Dynamics

United States tariffs in 2025 have introduced indirect cost pressures across the AUD medication supply chain by raising input and packaging component expenses. This has led manufacturers to diversify suppliers and incrementally localize supply chains, yet such moves also bring regulatory and operational complexities. For stakeholders, continuity of supply is critical for patient adherence and outcome guarantees. Payers and health systems are reacting by tightening contracting terms and favoring agents with robust value evidence. Leaders who view tariffs as a catalyst for supply resilience and scenario planning are better equipped to maintain stable access and payer relationships in this shifting environment.

Research Methodology & Data Sources

The report uses a blend of systematic secondary research and primary stakeholder interviews. Analyst teams map clinical, regulatory, and reimbursement landscapes, then validate findings with clinicians, payers, pharmacy leaders, and operational experts. Triangulation ensures accuracy across regions and settings while stress-testing for practical implementation.

Why This Report Matters

Aligns evidence-driven insights with executive priorities to support near-term and long-range decisions on market entry, resource allocation, and growth strategy.
Clarifies how tariff and supply dynamics influence adoption, enabling proactive risk management for supply continuity and access equity.
Equips leaders to drive competitive positioning through real-world implementation, provider enablement, and regional market adaptation.

Conclusion

As pharmacotherapy becomes a standard component of alcohol use disorder care, sustainable adoption now hinges on access reliability, structured follow-up, and alignment between stakeholders. Practical integration across care channels and regions will determine long-term success.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Medications for Alcohol Use Disorder Market, by Route of Administration

8.1. Injectables
8.1.1. Injectable Intramuscular
8.1.2. Injectable Subcutaneous
8.2. Oral Tablets

9. Medications for Alcohol Use Disorder Market, by Drug Class

9.1. Acamprosate
9.2. Baclofen
9.3. Disulfiram
9.4. Naltrexone
9.5. Topiramate

10. Medications for Alcohol Use Disorder Market, by Distribution Channel

10.1. Online
10.2. Offline

11. Medications for Alcohol Use Disorder Market, by End User

11.1. Hospitals
11.2. Research Institutes
11.3. Addiction Clinics

12. Medications for Alcohol Use Disorder Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Medications for Alcohol Use Disorder Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Medications for Alcohol Use Disorder Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Medications for Alcohol Use Disorder Market
16. China Medications for Alcohol Use Disorder Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Alkermes
17.6. Ambica Pharma
17.7. Amigoz Lifesciences
17.8. Care Formulation Labs Private Limited
17.9. Consern Pharma Limited
17.10. Dhritee Impex
17.11. Eisai Pharmaceuticals India Pvt Ltd
17.12. Intas Pharmaceuticals Ltd.
17.13. Johnlee Pharmaceuticals Pvt. Ltd.
17.14. Lifegenix (Div. of Lifecare Neuro Products Ltd.)
17.15. Mallinckrodt Pharmaceuticals
17.16. Marshall Healthcare
17.17. Odyssey Pharmaceuticals
17.18. Rusan Pharma
17.19. Salvavidas Pharmaceutical Pvt. Ltd.
17.20. Sanofi S.A.
17.21. Schwitz Biotech
17.22. Sun Pharmaceutical Industries Ltd.
17.23. Taj Pharmaceuticals
17.24. Teva Pharmaceutical Industries Ltd.

List of Figures

FIGURE 1. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 53. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 59. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 60. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 65. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 66. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 67. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 77. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 78. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 79. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 83. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 84. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 89. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 90. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 102. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 103. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 108. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 114. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 115. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 120. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 121. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 126. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 127. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 131. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 132. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 137. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 139. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 145. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Medications for Alcohol Use Disorder market report include:

Alkermes
Ambica Pharma
Amigoz Lifesciences
Care Formulation Labs Private Limited
Consern Pharma Limited
Dhritee Impex
Eisai Pharmaceuticals India Pvt Ltd
Intas Pharmaceuticals Ltd.
Johnlee Pharmaceuticals Pvt. Ltd.
Lifegenix (Div. of Lifecare Neuro Products Ltd.)
Mallinckrodt Pharmaceuticals
Marshall Healthcare
Odyssey Pharmaceuticals
Rusan Pharma
Salvavidas Pharmaceutical Pvt. Ltd.
Sanofi S.A.
Schwitz Biotech
Sun Pharmaceutical Industries Ltd.
Taj Pharmaceuticals
Teva Pharmaceutical Industries Ltd.

Table Information

Report Attribute	Details
No. of Pages	187
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 1.2 Billion
Forecasted Market Value ( USD ) by 2032	$ 2.17 Billion
Compound Annual Growth Rate	10.1%
Regions Covered	Global
No. of Companies Mentioned	21

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3505EUR$3,939USD£3,044GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3781EUR$4,249USD£3,283GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5125EUR$5,759USD£4,450GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6201EUR$6,969USD£5,385GBP

Medications for Alcohol Use Disorder Market - Global Forecast 2026-2032

Market Snapshot: Medications for Alcohol Use Disorder Market

Scope & Segmentation

Key Takeaways for Strategic Decision-Makers

Tariff Impact on Supply Chain & Market Dynamics

Research Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Market Snapshot: Medications for Alcohol Use Disorder Market

Scope & Segmentation

Key Takeaways for Strategic Decision-Makers

Tariff Impact on Supply Chain & Market Dynamics

Research Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Alcohol Use Disorder Market - Global Forecast 2026-2032

Alcohol Use Disorder Market Report and Forecast 2025-2034

Alcohol Use Disorder Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

Alcohol Use Disorder - Pipeline Insight, 2025

Alcohol Addiction - Pipeline Insight, 2025